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ABSTRACT
Loss of the tumor suppressor phosphatase and tensin homolog (PTEN) is
commonly observed in triple negative breast cancer (TNBC), leading to activation of
the phosphoinositide 3-kinase (PI3K) signaling to promote tumor cell growth and
chemotherapy resistance. In this study, we investigated whether adding a pan-PI3K
inhibitor could improve the cytotoxic effect of eribulin, a non-taxane microtubule
inhibitor, in TNBC patient-derived xenograft models (PDX) with loss of PTEN, and the
underlying molecular mechanisms. Three TNBC-PDX models (WHIM6, WHIM12 and
WHIM21), all with loss of PTEN expression, were tested for their response to BKM120
and eribulin, alone or in combination in vivo. In addition, the effect of drug treatment
on cell proliferation and cell cycle progression were also performed in vitro using
a panel of TNBC cell lines, including 2 derived from PDX models. The combination
of eribulin and BKM120 led to additive or synergistic anti-tumor effect in 2 of the 3
PDX models, accompanied by an enhanced mitotic arrest and apoptosis in sensitive
PDX models. In addition, the combination was synergistic in reducing mammosphere
formation, and markers for epithelial-mesenchymal transition (EMT). In conclusion,
PI3K inhibition induces synergistic anti-tumor effect when combined with eribulin,
by enhancing mitotic arrest and apoptosis, as well as, reducing the cancer stem cell
population. This study provides a preclinical rationale to investigate the therapeutic
potential for the combination of PI3K inhibition and eribulin in the difficult to treat
TNBC. Further studies are needed to identify the biomarkers of response for target
patient selection.

with metastatic breast cancer who have received at least
two prior chemotherapeutic regimens in the metastatic
setting and an anthracycline as well as a taxane in
either adjuvant or metastatic setting. In the phase III
EMBRACE study, eribulin was associated with superior
overall survival (OS) compared with physician's
choice chemotherapy in this patient population [8].
The efficacy of eribulin in TNBC was demonstrated in
the pooled analysis of 2 phase 3 studies (EMBRACE/
Study 305), which revealed 4.7 months improvement
in median survival with eribulin compared to control
chemotherapy (median OS: 12.9 vs 8.2 months; HR
0.74; P = 0.006) [9]. In addition to the induction of an

INTRODUCTION
Triple negative breast cancer (TNBC), defined by the
lack of estrogen receptor (ER), progesterone receptor (PR)
and HER2 gene amplification, represents approximately
15 to 20% of all breast cancer cases and is associated
with the worst prognosis compared to other breast cancer
subtypes [1-6]. The lack of molecularly targeted therapy
and the frequent occurrence of chemotherapy resistance
render TNBC a significant clinical challenge.
Eribulin mesylate (Halaven®, Eisai Inc) is a nontaxane microtubule dynamic inhibitor [7] that is Food
and Drug Administration (FDA) approved for patients
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irreversible mitotic block, eribulin has been shown to
impact tumor vascular remodeling [10] and inhibition of

epithelial-to-mesenchymal transition and metastasis in
experimental models [11] which has been implicated in

Figure 1: Eribulin in combination with BKM120 induces synergistic anti-tumor effect and target inhibition in
TNBC cells in vitro. Percentages of cell survival compared to vehicle control following 6 days of treatment with eribulin at indicated

concentrations, either alone or in combination with BKM120 (500 nM) were plotted for (A) BT549, (B) MDA-MB-231, (C) HCC1806,
(D) WHIM3, and (E) WHIM12. * indicates p<0.05 and ** indicates p<0.01. The combination of BKM120 and eribulin was significantly
more effective in reducing cell survival than each agent alone in these cell lines. Panel F shows the Western blot analysis for PI3K pathway
signaling, EMT, and apoptosis markers on cell lysates from BT549 and MDA-MB-231 following treatment with eribulin and BKM120,
alone or in combination for 48 hours. Abbreviations: V, Vehicle; B, BKM120; E, Eribulin; C, Combination. Compared to single agents,
the combination of BKM120 and eribulin was most effective in reducing the levels of pAKT and pS6 (markers of PI3K pathway activity),
N-Cadherin (EMT marker) and Survivin (an anti-apoptotic protein) and in the induction of apoptosis (Cleaved PARP).
www.oncotarget.com
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Anti-tumor activity of eribulin in combination
with BKM120 in TNBC PDX models in vivo

therapeutic resistance to cancer drugs including growth
factor receptor and PI3K inhibitors [12].
The phosphoinositide 3-kinase (PI3K) pathway
plays key regulatory roles in many cellular processes,
including cell survival, proliferation, differentiation and
angiogenesis [13, 14]. Hyper activation of the PI3K/
AKT pathway has been associated with TNBC [15, 16].
A significantly higher level of Akt phosphorylation has
been observed in TNBC patient specimens compared with
non–TNBC cases [15, 17]. Loss of PTEN or INPP4B
has been the most frequently implicated culprit for such
activation in TNBC [16, 18-21]. The high frequency of
PI3K pathway activation in TNBC renders it an attractive
therapeutic target. In addition, PI3K pathway activation
has also been associated with chemotherapy resistance
[22] and inhibition of PI3K pathway activity could
synergize the cytotoxicity of a variety of chemotherapy
agents [23-25]. In a cell-based, high-throughput screening
in a panel of twenty-five human cancer cell lines
representing a variety of tumor types, the PI3K inhibitor
BKM120 was identified to exert synergistic killing with
eribulin in both eribulin sensitive and resistant cancer
cell lines, 3 of which being TNBC [26]. The objectives of
this study is to assess the combinatory effect of eribulin
and BKM120 in TNBC cell lines and patient-derived
xenograft (PDX) models and to further elucidate the
underlying molecular mechanisms.

To validate the in vitro observation we evaluated
the anti-tumor and biomarker effect for eribulin
and BKM120 in TNBC PDX models that we have
previously characterized [27]. We first performed a
screening experiments using 1-3 mice per model for the
combination of eribulin and BKM120 in 6 TNBC PDX
models, including WHIM2, WHIM4, WHIM6, WHIM12,
WHIM21, and WHIM30 (Supplementary Figure 1). As
shown in Figure 3A, tumor volume reduction was observed
in 5 of the 6 models, including WHIM2 (average -21%
on day 11), WHIM4 (average -25% on day 15), WHIM6
(average -18% on day 11), WHIM21 (average -92% on day
18) and WHIM30 (average -66% on day 22) compared to
baseline at the best response. To discern the effect of single
agent versus combination, we treated 3 representative
models including, WHIM6 (Basal-like, WT TP53),
WHIM12 (Claudin-low, TP53 p.R248Q, PIK3CA pV105_
E109delinsT) and WHIM21 (Basal-like, TP53 p.P151H),
all with loss of PTEN expression and relatively high
PI3K pathway signaling [27] to either vehicle, eribulin,
BKM120, or the combination of eribulin and BKM120.
Combination therapy led to added or synergistic anti-tumor
effect in WHIM6 (Figure 3A). However, no obvious added
benefit was observed with the combination compared to
eribulin alone in WHIM12 and WHIM21 (Figure 3B
and 3C). Since eribulin alone at 1 mg/kg weekly dosing
potently inhibited xenograft tumor growth, which could
have prohibited further tumor growth inhibition with the
addition of BKM120, we reduced the dose of eribulin to
0.3 mg/kg weekly in WHIM21 to compare its anti-tumor
effect with or without BKM120. Indeed, the addition
of BKM120 to the lower dose of eribulin, either given
concurrently (eribulin on day 1 and BKM120 on days 1-5,
each week) or sequentially (eribulin on day 1 and BKM120
on days 2-5, each week) led to more effective tumor
growth inhibition compared to eribulin alone (Figure 3D).

RESULTS
Synergistic anti-tumor effect of eribulin and
BKM120 through enhanced target inhibition in a
panel of TNBC cell lines
To assess the anti-tumor effect of BKM120 and
eribulin, we tested a panel of TNBC cell lines (BT549,
HCC1806, and MDA-MB-231) as well as two PDX derived
cell lines (WHIM3 and WHIM12), for their response to
eribulin (0.1, 0.5 and 1nM) alone or in combination with
BKM120 (500nM) in vitro. Synergistic anti-tumor effect,
with combination index (CI) less than 1, between eribulin
and BKM120 was observed in all the tested TNBC cell lines
(Figure 1A-1E). Western Blot demonstrated that, compared
to individual agents, the combination of eribulin and
BKM120 was most effective in inhibiting PI3K pathway
signaling, as indicated by reduced pAKT and pS6 in
BT549 and MDA-MB-231 cells (Figure 1F). Additionally,
the combination reduced the level of the Epithelial to
Mesenchymal Transition (EMT) marker N-Cadherin more
effectively than eribulin alone, reduced the levels of the
anti-apoptotic protein Survivin, and enhanced apoptosis
as assessed by cleaved PARP (Figure 1F). Since eribulin
induces apoptosis by inhibiting mitotic progression, we
performed cell cycle analysis with flow cytometry, which
demonstrated that the combination of eribulin and BKM120
was most effective in inducing G2/M arrest (Figure 2).
www.oncotarget.com

The combination of eribulin and BKM120
enhanced mitotic arrest and apoptotic induction
in TNBC PDX models in vivo
To assess the molecular mechanisms for the
enhanced anti-tumor effect from the combination of
BKM120 and eribulin in TNBC in vivo, PDX xenografts
were harvested on day 3 following treatment with either
vehicle or eribulin (day 1) and BKM120 (days 1-3) alone
or in combination and subjected to biomarker analysis.
Consistent with the in vitro observation for the enhanced
G2/M phase arrest and apoptosis induction (Figure 1E
and Figure 2), combination therapy led to more effective
mitotic arrest, as shown by the increased proportion of
cells with pHistone H3 staining, and increased apoptosis
(increased cleaved PARP) in vivo (Figure 4A and 4B). As
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Figure 2: Eribulin in combination with BKM120 induces G2/M cell cycle arrest more effectively than either agent
alone in TNBC. Cell Cycle analysis was performed for (A) WHIM12-PDX derived cell line, (B) BT549 and (C) MDA-MB-231 TNBC
cell lines after treatment with vehicle, or BKM120 and eribulin, alone and in combination. Abbreviations: V, Vehicle; B, BKM120; E,
Eribulin; C, Combination. The combination of eribulin and BKM120 was most effective in inducing G2/M arrest.
www.oncotarget.com

3670

Oncotarget

CD24-population, with combination therapy being the
more effective (Figure 6C, 6D). Co-expression of CD44
and CD24 is frequently observed in basal/epithelial breast
cancer cells [28] and CD44+/CD24+ cells have shown to
be more invasive and tumorigenic than CD44+/CD24neg
cells and possess stemness characteristics of self-renewal
and differentiation in multiple cancer types [29, 30]. This
is in contrast to paclitaxel, another microtubule inhibitor,
which did not inhibit these subsets of cell population,
either administered alone or in combination with BKM120
(Supplementary Figure 2).

predicted, treatment with BKM120 reduced PI3K pathway
signaling indicated by the levels of pAKT and treatment
with eribulin inhibited EMT marker N-cadherin (Figure
4C and 4D) as observed in vitro (Figure 1E).

Eribulin and BKM120 synergistically inhibits
mammosphere formation and stem cell
population
The effect of eribulin and BKM120 on N-cadherin
in TNBC cell lines suggest that the combination is
synergistic in reducing EMT. As EMT is associated with
cancer cell stemness, we hypothesize that the combination
therapy is synergistic in reducing the cancer stem cell
population. We, therefore, examined the effect of eribulin
and BKM120, alone or in combination, on mammosphere
formation in low attachment plates as well as on CD44+/
CD24-neg/low sub-population, the putative stem cell
population, in TNBC cell lines. As demonstrated in Figure
5, the combination of eribulin and BKM120 inhibited
mammosphere formation synergistically in BT549,
and MDA-MB-231, as well as, in the ex-vivo cultured
WHIM6 and WHIM12-PDX cells. In addition, eribulin
in combination with BKM120 was more effective than
each agent alone in reducing the percentage of the CD44+/
CD24neg sub-population in MDA-MB-231 cells (Figure
6A, 6B). Interestingly, in BT549 cells, treatment with
eribulin and BKM120 reduced the percentage of CD44+/

DISCUSSION
Resistance to chemotherapy is associated with
poor clinical outcomes in patients with TNBC, for which
targeted therapies are lacking [1, 31-32]. In this study, we
demonstrated that PI3K inhibition in combination with an
anti-mitotic chemotherapy agent eribulin led to enhanced
target inhibition, reduction of cancer stem cell population,
and synergistic cytotoxic effect in TNBC cell lines and
PDX models, providing a preclinical rationale for further
clinical investigation.
PI3K pathway signaling plays key regulatory
roles in many cellular processes, including cell survival,
proliferation, differentiation and angiogenesis [13, 14].
Aberrant activation of the PI3K pathway signaling is
frequently observed in TNBC [15, 21]. Compared to other

Figure 3: Eribulin in combination with BKM120 inhibits tumor growth in TNBC PDXs. Tumor volume changes with time

compared to baseline following treatment with either vehicle, eribulin (1 mg/kg, IP, day 1 each week x 3), BKM120 (30 mg/kg, PO, days
1-5 each week x3) or the combination of eribulin and BKM120 in (A) WHIM6, (B) WHIM12 and (C) WHIM21 TNBC PDX models in
vivo (n=6). (D) Tumor volume changes with time compared to baseline following treatment with either eribulin (0.3 mg/kg, IP, day 1 each
week x 3), or the combination of eribulin and BKM120 administered concurrently (eribulin 0.3 mg/kg, IP, day 1 and BKM120 30 mg/kg,
PO, days 1-5 each week) or sequentially (eribulin 0.3 mg/kg, IP, day 1 followed by BKM120 30 mg/kg, PO, on days 2-5 each week) in
WHIM21. * indicates p<0.05 and **** indicates p<0.0001.
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subtypes, TNBC is associated with significantly higher
levels of AKT phosphorylation, as well as, PI3K signaling
activity assessed by either gene expression signature or
RPPA phosphoproteomic signature [16, 17, 33]. Common
PI3K pathway gene abnormalities identified in the TCGA
TNBC data set included PIK3CA mutation (7%), as well
as, loss/mutations of PTEN (35%) and loss of INPP4B
(16%), which are the major causes of pathway signaling
activation [33]. Consistent with the importance of PI3K
pathway in TNBC tumorigenesis, PTEN inactivation leads
to “basal-like” breast cancer in animal models [34, 35].
PI3K pathway signaling activation has been
identified to be a key resistance mechanism to
chemotherapy as demonstrated in a recent study which

investigated genomic alterations and gene expression
profiles associated with chemotherapy resistance in
patients with TNBC [36]. In addition, inhibition of PI3K
pathway components has been shown to enhance the
sensitivity to various chemotherapy agents in preclinical
models [26, 37-42]. For example, significant synergisms
in terms of reducing cell proliferation and induction
of apoptosis were observed with the combination
of ipatasertib, an AKT inhibitor, or taselisib, a PI3K
inhibitor, and anti-microtubule agents including paclitaxel,
vinorelbine, and eribulin in PIK3CA mutant breast cancer
cell lines in vitro [40]. Although the first-generation
mTOR or PI3K inhibitors have generated mixed results
when combined with paclitaxel in clinical trials [43],

Figure 4: Eribulin in combination with BKM120 induces more apoptosis, mitotic cell cycle arrest and target inhibition
in TNBC PDXs. Representative pictures for IHC analysis of Cleaved-PARP and phospho-histone3 (pH3) following 3 days of therapy with

either vehicle or eribulin and BKM120, alone or in combination are shown for (A) WHIM6 and (B) WHIM21 PDX tumors. Combination
therapy was associated with enhanced mitotic arrest (pH3) and apoptosis (Cleaved PARP). Western blot analysis for pAKT, AKT and
N-Cadherin was performed on post treatment tumor lysates for (C) WHIM6 and (D) WHIM21. Abbreviations: V, Vehicle; B, BKM120; E,
Eribulin; C, Combination. Treatment with single agent BKM120 and eribulin reduced the levels of pAKT and N-Cadherin, respectively.
The combination of BKM120 and eribulin reduced the levels of both pAKT and N-Cadherin.
www.oncotarget.com
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Figure 5: Eribulin alone or in combination with BKM120 inhibited mammosphere formation in TNBC cell lines in
vitro. Mammosphere formation was assessed following 6 days treatment with either vehicle, eribulin, BKM120, or the combination

of eribulin and BKM120 for (A) BT549, (B) MDA-MB-231, (C) ex vivo cultured WHIM6 and (D) WHIM12 PDX derived cell line.
Representative photographs were shown. The combination of eribulin and BKM120 was most in inhibiting mammosphere formation.
www.oncotarget.com
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Figure 6: Eribulin in combination with BKM120 inhibited stem cell population in TNBC lines in vitro. Representative
FACS analysis of stem cell population in (A) MDA-MB-231 and (C) BT549 cells after eribulin and BKM120 single and combination
treatment for 48 hours. Gates were adjusted using unstained and isotype secondary controls. (B) and (D) shows the quantification of cellular
subsets by CD44 and CD24 staining for MDA-MB-231 and BT549, respectively, from three independent experiments. * indicates p<0.05
and ** indicates p<0.01.
www.oncotarget.com
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more encouraging data has been observed with direct
AKT inhibitors in the neoadjuvant [44], as well as,
metastatic settings for the treatment of TNBC [45]. In
this paper, we show that BKM120 enhances the cytotoxic
effect of the non-taxane microtubule inhibitor eribulin
in TNBC PDX models with loss of PTEN, accompanied
by enhanced mitotic arrest and apoptosis induction. Our
data provides in vivo validation for the synergistic effect
of this combination observed in a cell-based assay [26]
and is in line with a prior study presented in an abstract
form in PIK3CA mutant breast cancer xenograft models
[42]. These results are in support of ongoing and future
clinical trial investigations of eribulin with PI3K pathway
inhibitors such as NCT02723877 and NCT02616848 in
this difficult to treat patient population.
We were particularly interested in eribulin as
chemotherapy agent because of its unique mechanisms of
action and potential effect on EMT. There is increasing
evidence in the literature indicating that CSCs play a
crucial role in therapy resistance [46-48] and that activation
of the PI3K/AKT pathway is indispensable for maintaining
the stemness and chemoresistance of breast CSCs [49, 50].
Moreover, previous studies have also shown that PI3K
inhibition sensitizes CSCs to chemotherapy and molecular
targeted therapy in several cancers including leukemia,
hepatocellular carcinoma and breast cancer [51-53]. In this
study, we showed that BKM120 and eribulin each reduced
mammosphere formation and CSC population as a single
agent in vitro, but the combination was more effective.
We demonstrated that the combination of eribulin and
BKM120 was most effective in inhibiting downstream
signaling of PI3K and EMT markers, accompanied by
enhanced mitotic arrest and apoptosis induction.
The limitations of this study includes the small
number of PDX models tested and the lack of predictive
marker biomarkers for the combination of eribulin and
BKM120. A larger cohort of PDX models are needed for
biomarker development. In addition, BKM120 is no longer
being developed clinically due to its associated side effects.
However, this is a proof of concept study demonstrating
the potential of eribulin and PI3K inhibitor combinations.
Future studies will focus on other clinical PI3K inhibitors.

a density of 3,000 cells per well in 96-well plates in
RPMI-1640 medium supplemented with 10% FBS,
1% glutamine, and 1% penicillin-streptomycin for 24
hours. Cells were treated with vehicle, or varying doses
of eribulin (0-1 nM) either alone or in combination with
BKM120 (500 nM) for 6 days followed by Alamar Blue
Assay. Each experiment was repeated twice in triplicate.
Synergistic or additive activity between eribulin and
BKM120 was determined by calculating combination
index values using Compu Syn software.

Cell lines
BT549, MDA-MB-231, and HCC1806 were
purchased from ATCC. WHIM3 (also named WU-BC3)
and WHIM12 were established from PDX models and
were described previously [27, 54].

Western blotting
Cell lines treated with eribulin or BKM120 were
seeded in a 6-well plate at a density of 0.5 × 106, adhered
overnight and treated with DMSO (0.1%), eribulin at
5nM and BKM120 at 500 nM concentration for 48
hours. Cells were then harvested and lysed with 100
μL buffer containing 50 mmol/L Tris-HCl, pH 7.5, 150
mmol/L NaCl, 2 mmol/L EDTA, 1% Triton, 1 mmol/L
phenylmethylsulfonylfluoride, and Protease Inhibitor
Cocktail (Sigma) for 20 min on ice. Lysates from cell lines
or PDX xenografts were cleared at 10,000 rpm for 15 min,
boiled, separated on 12% SDS gels, and transferred to a
nitrocellulose membrane followed by overnight incubation
with primary antibodies against pAKT473, AKT, pS6240/244,
S6, N-Cadherin, cleaved PARP, survivin (BRIC5) and
β-actin. Protein bands were visualized after 1 hour
incubation with HRP-conjugated secondary antibodies and
development with ECL (GE Healthcare).
Primary antibodies against phospho-AKTS473 (Cat.
no. 4060), AKT (Cat. no. 4685), phospho- S6Ser240/244 (Cat.
no. 2215), S6 (Cat. no. 2217), Cleaved PARP (Asp214)
(Cat. no. 9541), and β-actin (Cat. no. 4970) were purchased
from Cell Signaling Technology. Other primary antibodies
included antibodies against N-Cadherin (Cat. no. ab18203;
Abcam), survivin (Cat. no. sc-17779; Santa Cruz), and p21
(Cat. no. sc-6246; Santa Cruz). Secondary horseradish
peroxidase (HRP)-conjugated anti-rabbit (Cat.7074) and
anti-mouse antibodies (Cat. no. 7076) for Western Blot
were purchased from Cell Signaling Technology.

MATERIALS AND METHODS
Chemicals
BKM120 (Catalog no. CT-BKM120) was purchased
from Chemietek. Eribulin was provided by Eisai. Paclitaxel
(Catalog no. S1150) was purchased from Selleckchem. All
drugs were prepared in stock solution of 10 mM in dimethyl
sulfoxide (DMSO; Sigma) for in vitro experiments.

Flow cytometry cell cycle analysis
BT549, MDA-MB-231 and WHIM12 cells were
seeded in 6-well plate at a density of 500,000 cells/
well in 2ml RPMI medium. After 24 hours, cells were
treated with vehicle, or BKM120 (500nM) and eribulin
(5nM), either alone or in combination for 48 hours. Cells
were then harvested and analyzed for cell cycle analysis

In vitro cytotoxic assay
For cytotoxic assay, BT549, MDA-MB-231,
HCC1806, WHIM3, and WHIM12 were seeded at
www.oncotarget.com
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using Invitrogen Propidium Iodide staining buffer. Data
from three independent experiments were used for the
quantification of cellular subsets in Figure 6B, Figure 6D,
Supplementary Figure 2B, and Supplementary Figure 2D.

Cells were seeded in a 6-well plate at a density
of 0.5 × 106, adhered overnight, followed by treatment
with DMSO (0.1 %), eribulin at 5nM and BKM120 at
500 nM concentration for 48 hours. After 48 hours, cells
were harvested for CD44/C24 expression analysis by
FACS. To evaluate CD24 and CD44 expression, cells
were harvested, washed with FCS buffer once. Then,
100,000 cells again resuspended in 1ml FCS buffer and
antibodies against CD44-PE (10ul) (Cat. no. 555479; BD
Pharmingen) and CD24 Alexa-Flour 647- (2.5ul) (Cat. no.
311109; BioLegend) were added for 30 minutes at room
temperature in the dark. After 30 minutes, cells were
washed with PBS two times and resuspended in 1ml FCS
buffer and analyzed by FACS. Then cells were analyzed
on a BD FACS Calibur flow cytometer. These data were
analyzed by Flo-Jo and at least 10,000 events per sample
were collected. Appropriate controls were included in
the experiments. Unstained samples, Isotype-Secondary
control, CD44 and CD24 alone staining.

For the initial screening experiments, 6 PDX models
with each passaged in 1-3 mice were allowed to grow to
approximately 1 cm in diameter, then treated with eribulin
(0.75 mg/kg, IP days 1, 3 and 8) and BKM120 (30 mg/kg,
PO, days 1-5 then days 7-8). For tumor growth experiments
shown in Figure 3A-3C, xenografts were allowed to grow
to approximately 0.5 cm in the maximum diameter. Mice
were then divided into 4 treatment groups (n = 6 mice in
each group): Vehicle (vehicle diluents were 0.9% sodium
chloride saline for eribulin and 0.5% (w/v) methyl cellulose
0.5% (v/v) Tween 80 in water for BKM120), eribulin alone
(1 mg/kg, IP on day 1 each week), BKM120 alone (30mg/
kg, oral gavage, days 1-5 each week) or the combination of
eribulin and BKM120 (at the same dose and schedule as in
single agent therapy) for a total of 3 weeks. For WHIM21
tumor response shown in Figure 3D, tumor bearing
mice (n=6 per group) were treated with either eribulin
(0.3mg/kg) or the combination of eribulin and BKM120
concurrently (eribulin 0.3 mg/kg, IP, day 1 and BKM120
30 mg/kg, PO, days 1-5 each week) or sequentially
(eribulin 0.3 mg/kg, IP, day 1 followed by BKM120 30
mg/kg, PO, on days 2-5 each week) for 3 weeks. Two
dimensional measurements (length and width) using
Traceable Digital Calipers were performed 2-3 times each
week. The following formula was used to calculate tumor
volume: tumor volume (cm3) = (length × width2) × 0.5. For
biomarker studies tumor bearing mice were treated with
either Vehicle (n = 2), eribulin (n=2; 1 mg/kg/day,IP day1),
BKM120 (n=2, 30 mg/kg, days 1, 2, 3), or the combination
of eribulin and BKM120 (the same dosing and schedule
as single agent therapy). Tumors were harvested 2 hours
after day 3 of therapy. Each xenograft tumor was cut into
2 pieces with one piece flash frozen for tumor lysate, and
the second piece fixed in 10% neutral buffered formalin
and embedded in paraffin blocks. All animal studies were
carried out using the appropriate NIH animal care, and
the animal studies protocol was approved by the Animal
Studies Committee of Washington University.

Mammosphere culture

Statistical analysis

Sphere formation was performed in ultralow
attachment 6-well plates (Corning) with DMEM/F12 stem
cell medium. (Thermo scientific). BT549, MDA-MB-231,
WHIM12 and WHIM6-PDX derived cells were seeded at
the density around 1000 cells/well in ultralow attachment
6-well plates and cultured at 37°C in 5% CO2. After 24
hours, cells were treated with vehicle, BK1M20 (500nM)
and Eribulin (5nM) for 6 days. Colony formation was
assessed and photomicrograph after 6 days of treatment.

Statistical analyses were conducted using Graphpad
Prism software. Results are expressed as mean ± SEM.
Statistical significance was determined by Student paired
t test for in vitro data respectively. Tumor volume data
were compared using two-way ANOVA. P ≤ 0.05 was
considered significant.

Immunohistochemistry
IHC for pHistone H3 and cleaved PARP were
conducted on 5 μm tissue sections from paraffinembedded tumor as described previously using the
EnVision + Single Reagents HRP-Rabbit (Dako) and
REAL substrate buffer (REAL DAB + chromogen, Dako)
[54]. The primary antibodies and dilutions are as follows:
pHistone H3 (Ser 10) antibody (1:200; Cat. no. 06-570;
Millipore), and cleaved PARP antibody (1:200, Cat. no.
9541; Cell Signaling).

Analysis of CD44+ /CD24– cell subpopulation

Abbreviations
PI3K: Phosphatidylinositol-3-Kinase; PTEN:
Phosphatase and tensin homolog; TNBC: triple negative
breast cancer; PDX: patient derived xenograft; WHIM:
Washington University Human-in-Mouse; EMT:
epithelial-mesenchymal transition; ER: estrogen
receptor; PR: progesterone receptor; HER2: human
epidermal growth factor receptor 2; FDA: Food and Drug

In vivo xenografts-drug therapy and assessment
PDX models were passaged on each side of the
fourth mammary fat pad in female NU/J homozygous mice
(Charles River Cat. No. 088) to propagate xenografts for
tumor growth and biomarker response with drug therapy.
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Administration; RPPA: reverse phase protein array; NU/J:
homozygous nude; IP: intraperitoneal injection; PO:
per os (meaning by mouth); NIH: National Institutes of
Health; SEM: standard error of the mean;

preclinical models for selection of targeted therapies. J
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